Clinically significant ILD is believed to occur in 5%-10% of patients with RA, but robust data are lacking on how to best predict which patients face the highest risk for RA-associated ILD.
Galecto will stop developing its therapy for a disease that causes lung scarring after it failed to meet the main goal of a midstage study, the drug developer said on Tuesday.